Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3895671 | 0.86 | TP53 (0.72) | TP53SMN1; SMN2TSHRGPBAR1PKM | |
| SCHEMBL4322189 | 0.82 | TP53 (0.69) | TP53SMN1; SMN2TSHRGPBAR1PKM | |
| SCHEMBL3883649 | 0.80 | GPBAR1 (0.69) | TP53SMN1; SMN2TSHRGPBAR1ALOX15 | |
| SCHEMBL3886598 | 0.78 | TP53 (0.53) | TP53SMN1; SMN2TSHRGPBAR1PKM | |
| SCHEMBL6953639 | 0.77 | GAA (0.45) | TP53SMN1; SMN2TSHRMAPT | |
| SCHEMBL3342133 | 0.75 | LMNA (0.58) | TP53GPBAR1PKM | |
| SCHEMBL17782167 | 0.75 | TP53 (0.56) | TP53TSHRGPBAR1PKMALOX15 | |
| SCHEMBL7928701 | 0.75 | ADRA1A (0.52) | TP53GPBAR1 | |
| SCHEMBL5661329 | 0.75 | ADRA1A (0.52) | TP53GPBAR1 | |
| SCHEMBL8004288 | 0.75 | ADRA1A (0.52) | TP53GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592357-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1718638-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080058384-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1718638-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082890-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058384-A1 | Novel Compounds | ARHGDIB, TNK2, ROCK2 | TP53 3036/4885SMN1; SMN2 3861/4885TSHR 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.